In the available literature, BBB disruption has been recognized as an early indicator of cognitive dysfunction in humans, for some individuals with early cognitive dysfunction may present cerebral capillary damage and hippocampal BBB disruption without the presence of amyloid-beta peptides and/or tau biomarker changes that are typical in AD [47]. The gene discussed is MAPT; the disease is Alzheimer disease.